Furthermore, retrospective review of 113 patients with metastatic prostate cancer found that increased MOR expression and greater opioid requirement were associated with decreased PFS and OS likely due to increased MOR‐induced signaling upon opioid exposure.27 The gene discussed is OPRM1; the disease is metastatic prostate carcinoma.